In preclinical experimental models, significant and sustained anti-tumor activity in vitro and in vivo can be obtained with the combination of anti-EGFR agents and other anti-signaling agents, such as inhibitors of the cAMP-dependent protein kinase[27,28], an antisense oligonucleotide targeting VEGF[29], or the monoclonal antibody trastuzumab, which targets ErbB-2[30,31]. Here, EGFR is linked to neoplasm.